The Technical Analyst
Harpoon Therapeutics Inc [HARP]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Harpoon Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.57% $1.880
Last updated: 3 jul 2022 - 19:06
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 62.20 mill |
| EPS: | -2.31 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 33.08 mill |
| Avg Daily Volume: | 0.287 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.66 (94.95%) $1.785 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $0.228 ( +/- 12.13%) Range: 1.652 - 2.11 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-22 | Viney Joanne L. | Buy | 37 500 | Director Stock Option (Right to Buy) |
| 2022-06-22 | Viney Joanne L. | Buy | 10 167 | Director Stock Option (Right to Buy) |
| 2022-06-22 | Robbins Andrew R | Buy | 10 167 | Director Stock Option (Right to Buy) |
| 2022-06-22 | Hunt Ronald | Buy | 32 142 | Director Stock Option (Right to Buy) |
| 2022-06-22 | Hunt Ronald | Buy | 10 167 | Director Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 51.10 |
| Last 100 transactions |
| Buy: 1 563 866 | Sell: 846 095 |
Forecast:
16:00 - $1.870
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.870
Forecast 2: 16:00 - $1.870
Forecast 3: 16:00 - $1.870
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.880 (-1.57% ) |
| Volume | 0.112 mill |
| Avg. Vol. | 0.287 mill |
| % of Avg. Vol | 39.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HARP
16 Signals | Accuracy: 25.00% | Accuracy Buy: 0.00% | Accuracy Sell: 50.00%
Avg return buy: -0.57 % | Avg return sell: -0.55 %
$1 invested is now $0.96 or -4.49% since 30-06-22
| Date | Signal | @ | Closed | % | Jul 1 - 15:59 | sell | $1.880 | N/A | Active |
|---|---|---|---|---|
| Jul 1 - 15:56 | buy | $1.900 | $1.880 @ Jul 1 - 15:59 | -1.05% |
| Jul 1 - 15:55 | sell | $1.885 | $1.900 @ Jul 1 - 15:56 | 0.80% |
| Jul 1 - 15:37 | buy | $1.889 | $1.885 @ Jul 1 - 15:55 | -0.19% |
| Jul 1 - 13:49 | sell | $1.910 | $1.889 @ Jul 1 - 15:37 | -1.12% |
| Jul 1 - 13:40 | buy | $1.910 | $1.910 @ Jul 1 - 13:49 | 0.00% |
| Jul 1 - 11:38 | sell | $1.935 | $1.910 @ Jul 1 - 13:40 | -1.29% |
| Jul 1 - 11:04 | buy | $1.935 | $1.935 @ Jul 1 - 11:38 | 0.00% |
| Jul 1 - 10:10 | sell | $1.915 | $1.935 @ Jul 1 - 11:04 | 1.04% |
| Jul 1 - 10:02 | buy | $1.950 | $1.915 @ Jul 1 - 10:10 | -1.79% |
HARP
Latest Press Releases
2022-05-26 17:00:00 - Press Release
Harpoon Presents Interim Data From Ongoing Dose Escalation Portion Of T Cell Engager Hpn328 Clinical Trial At 2022 Asco Annual Meeting
South san francisco, calif., may 26, 2022 (globe newswire) -- harpoon therapeutics, inc. (nasdaq: harp), a clinical-stage immunotherapy company developing novel t cell engagers, today announced interim safety and efficacy data from the ongoing dose escalation and expansion study evaluating hpn328, harpoon's half-life extended tritac® targeting delta-like canonical notch ligand 3 (dll3), for the treatment of sclc and other neuroendocrine cancers. the first scientific presentation of these interim data will be featured in a poster session at the american society of clinical oncology (asco) annual meeting 2022, taking place in chicago from june 3-7.
2022-05-12 16:05:00 - Press Release
Harpoon Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update
South san francisco, calif., may 12, 2022 (globe newswire) -- harpoon therapeutics, inc. (nasdaq: harp), a clinical-stage immunotherapy company developing novel t cell engagers, today reported financial results for the first quarter ended march 31, 2022 and provided a corporate update.
2022-05-02 09:00:00 - Press Release
Harpoon Therapeutics And Roche To Collaborate On Clinical Trials To Study Novel Immuno-oncology Combination For Small Cell Lung Cancer
Hpn328, harpoon's dll3-targeting t cell engager, to be evaluated in combination with anti-pd-l1 antibody in patients with small cell lung cancer hpn328, harpoon's dll3-targeting t cell engager, to be evaluated in combination with anti-pd-l1 antibody in patients with small cell lung cancer
2022-04-12 07:30:00 - Press Release
Harpoon Therapeutics Presents Preclinical Data For Tritac-xr Platform That Supports Potential For Improved Safety By Minimizing Cytokine Release Syndrome
Tritac-xr demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index tritac-xr demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index
2022-04-07 16:05:00 - Press Release
Harpoon Therapeutics Announces Leadership Change
South san francisco, calif., april 07, 2022 (globe newswire) -- harpoon therapeutics, inc. (nasdaq: harp), a clinical-stage immunotherapy company developing novel t cell engagers, today announced that natalie sacks, m.d., chief medical officer, will be leaving the company effective june 1, 2022. dr. sacks will serve as a consultant to harpoon through the end of the year.
Latest News
2022-05-16 16:26:05 - PennyStocks
Best Penny Stocks to Buy This Week? 3 to Watch Right Now
Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-12 18:48:31 - Zacks Investment Research
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-07 07:30:00 - GlobeNewsWire
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference. The discussion will take place on Thursday, April 14, 2022 at 2:30 p.m. ET (11:30 a.m. PT).
2022-03-10 18:48:18 - Zacks Investment Research
Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -43.48% and 38.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-02-09 07:30:00 - GlobeNewsWire
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The discussion will take place on Wednesday, February 16, 2022 at 5 p.m. ET (2 p.m. PT).
2022-01-12 11:31:17 - Zacks Investment Research
Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 274.4% in Harpoon Therapeutics, Inc. (HARP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2021-12-13 12:11:20 - Benzinga
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma. Data were presented at the American Society for Hematology (ASH) Annual Meeting and Exposition.
2021-12-07 07:30:00 - GlobeNewsWire
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs.
2021-11-10 19:50:14 - Zacks Investment Research
Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-04 09:00:00 - GlobeNewsWire
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held virtually and in person in Atlanta, Ga. from December 11-14, 2021.